




**Figure S1:**<sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA accumulation in mice treated with ConA. Representative coronal sections of vehicle- and ConA-treated immunocompetent or immunocompromised mice injected with <sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA.




**Figure S2:** Hepatic <sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA accumulation are unaffected in immunocompromised mice treated with ConA. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated immunocompromised mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated immunocompromised mice injected with <sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. ns: not significant.



**Figure S3:** GLUT1, RBKS, and dCK protein levels are unaffected in liver sections from immunocompromised mice treated with ConA compared to vehicle-treated mice. GLUT1, RBKS, and dCK immunostained vehicle- and ConA-treated immunocompromised mouse liver sections.



**Figure S4:** Hepatic <sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA accumulation are unaffected in immunocompromised mice treated with adenovirus. (A) Histological and immunohistochemical analyses of liver sections from pretreatment and adenovirus-treated immunocompromised mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of pretreatment and adenovirus-treated immunocompromised mice injected with <sup>18</sup>F-FDG, <sup>18</sup>F-DFA, and <sup>18</sup>F-FAC. Quantification represents radiotracer accumulation in the liver normalized to a background organ. ns: not significant.



**Figure S5:** <sup>18</sup>F-FDG, <sup>18</sup>F-FAC, and <sup>18</sup>F-DFA accumulation in a mouse model of viral hepatitis. Representative coronal sections of pretreatment and adenovirus-treated mice injected with <sup>18</sup>F-FDG, <sup>18</sup>F-DFA, and <sup>18</sup>F-FAC.